NEW YORK (GenomeWeb News) – Myriad Genetics said during its analyst and investor day today that it will launch a new multi-hereditary cancer panel, called myRisk Hereditary Cancer, by the end of this year that will replace its existing BRACAnalysis and other hereditary cancer tests by the summer of 2015.

The new panel will initially focus on breast, colon, ovarian, endometrial, and pancreatic cancer, as well as melanoma, and will expand to lung, prostate, and other cancers in the future, Mark Capone, president of Myriad Genetics Laboratories, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.